Music Banter - View Single Post

DwnWthVwls · 07-22-2018, 02:45 PM

https://www.researchgate.net/profile...-the-risks.pdf - Free Download

Quote:

Chemotherapy-induced nausea and vomiting.
Up to 80% of patients who receive chemotherapy
experience CINV, which occurs
from 24 hours to 7 days after receiving such
therapy.26 CINV negatively influences a
patient’s QOL and may impact the decision
to continue with chemotherapy. Use of MM
can help to diminish vomiting by binding to
central CB1 receptors and averting the proemetic
effects of dopamine and serotonin.
alone. All active treatments reduced nausea
compared with placebo; there was no difference
between active treatment groups. This
study was limited by low enrollment.
Tramèr et al28 conducted a systematic
review of 30 randomized comparisons
of MM with placebo or antiemetics. The
reviewed studies were completed between
1975 to 1997 and analyzed a total of 1,366
patients. Nabilone was evaluated in 16 trials;
dronabinol was utilized in 13 trials; and IM
levonantradol, a synthetic cannabinoid analog
of dronabinol, was used in 1 trial. These
agents were found to be more effective as
an antiemetic compared with prochlorperazine,
metoclopramide, chlorpromazine,
thiethylperazine,
haloperidol, domperidone,
or alizapride. In addition, 38% to 90% of
patients in these studies preferred MM over
the traditional antiemetics.
A Cochrane review29 suggested that
MM may be a viable option for treatmentresistant
CINV; however, further studies are
needed because current studies have methodological
limitations.